Cytokeratin 18 Antibody / CK18 Antibody

Cytokeratin 18 Antibody Overview

Cytokeratin 18 Antibody reagents target keratin 18 (KRT18), a type I intermediate filament protein widely expressed in simple epithelial cells. KRT18 typically pairs with keratin 8 to form heterodimers that stabilize cytoskeletal networks, support intracellular organization, and protect cells against mechanical and apoptotic stress.

KRT18 is expressed in many epithelial tissues, including the liver, pancreas, gastrointestinal tract, and mammary gland. Pathologically, elevated KRT18 expression is common in carcinomas, while caspase-cleaved KRT18 fragments serve as biomarkers of apoptosis and cell turnover. The Cytokeratin 18 Antibody is therefore an essential reagent in epithelial biology, cancer research, and clinical diagnostics, while the CK18 Antibody supports applications in hepatology, oncology, and translational research.

Why Choose Cytokeratin 18 Antibodies from NSJ Bioreagents?

NSJ Bioreagents supplies Cytokeratin 18 Antibodies validated for immunohistochemistry, immunofluorescence, western blotting, ELISA, and flow cytometry. Each Cytokeratin 18 Antibody undergoes rigorous validation to ensure specificity, reproducibility, and minimal background staining.

By selecting Cytokeratin 18 Antibodies from NSJ Bioreagents, researchers gain tools optimized for clarity and consistency. Our antibodies provide strong cytoplasmic staining in simple epithelial tissues, reproducible detection in lysates, and robust performance across platforms. Comprehensive datasheets, suggested controls, and validated protocols further enhance reproducibility in both research and clinical applications.

Applications of Cytokeratin 18 Antibodies

The Cytokeratin 18 Antibody supports a broad spectrum of biomedical and clinical applications.

1) Oncology and Tumor Biology

• Cytokeratin 18 Antibodies detect KRT18 in carcinomas of the liver, breast, pancreas, and colon.

• The Cytokeratin 18 Antibody highlights tumor progression and epithelial lineage.

• CK18 Antibody reagents are used in biomarker studies for cancer prognosis and therapy monitoring.

2) Pathology and Diagnostics

• Cytokeratin 18 Antibodies confirm epithelial origin in biopsies.

• The Cytokeratin 18 Antibody supports tumor classification in pathology workflows.

• CK18 Antibody reagents validate diagnostic markers in oncology.

3) Apoptosis and Cell Death Research

• Cytokeratin 18 Antibodies detect caspase-cleaved KRT18 fragments (M30 and M65 assays).

• The Cytokeratin 18 Antibody supports studies of apoptosis in oncology and hepatology.

• CK18 Antibody reagents provide translational value in drug development studies.

4) Hepatology and Liver Disease

• Cytokeratin 18 Antibodies highlight KRT18 expression in hepatocytes and bile duct epithelia.

• The Cytokeratin 18 Antibody supports biomarker development for liver injury.

• CK18 Antibody reagents are applied in research on non-alcoholic fatty liver disease and cirrhosis.

5) Developmental and Stem Cell Biology

• Cytokeratin 18 Antibodies track epithelial lineage differentiation in embryogenesis.

• The Cytokeratin 18 Antibody validates epithelial identity in stem cell and organoid models.

• CK18 Antibody reagents support regenerative research in epithelial tissues.

6) Translational and Clinical Research

• Cytokeratin 18 Antibodies are used in biomarker-driven clinical studies.

• The Cytokeratin 18 Antibody supports patient monitoring in precision oncology.

• CK18 Antibody reagents provide reproducibility in translational medicine workflows.

Why Are Cytokeratin 18 Antibodies Important?

KRT18 plays essential roles in cytoskeletal stability, apoptosis, and epithelial biology. The Cytokeratin 18 Antibody enables precise detection of this protein, while the CK18 Antibody supports its use across pathology, oncology, and translational medicine.

In oncology, Cytokeratin 18 Antibodies highlight tumor progression and apoptosis biomarkers. In hepatology, the Cytokeratin 18 Antibody provides insight into liver injury and regenerative potential. In developmental biology, CK18 Antibody reagents support studies of epithelial lineage specification.

Clinically, caspase-cleaved KRT18 fragments serve as important biomarkers for apoptosis, liver disease, and cancer therapy monitoring. Cytokeratin 18 Antibodies ensure reproducibility and reliability, bridging basic discoveries with diagnostic and translational applications.

Conclusion

Cytokeratin 18 is a key intermediate filament protein with major roles in epithelial stability, apoptosis, and disease. The Cytokeratin 18 Antibody equips scientists and clinicians with validated reagents for detecting KRT18 in oncology, hepatology, and developmental biology, while the CK18 Antibody provides complementary applications in translational medicine. By ensuring specificity and reproducibility, these antibodies remain indispensable for advancing epithelial research and improving diagnostic accuracy.